Table 5.
Notch-associated lncRNAs in relation to multi-drug resistance in CRC
| Notch-associated lncRNA |
Multi-drug resistance in CRC | Refs. | |||
|---|---|---|---|---|---|
| Chemotherapy used | miR sponged | Target protein(s) | Effect on apoptosis | ||
| LINC00152 | Oxaliplatin |
miR-193a-3p miR-139-5p |
-ERBB4 with AKT signal activation -Notch1 which induces upregulating of MRP-1 and BcL-2 |
Suppressed | [25, 127, 194] |
| LINC00707 |
5-FU topotecan, cisplatin & Astragaloside IV |
miR-206 |
- Bcl-2 -Notch3 |
Lower apoptosis rate | [130, 199–201] |
| DSCAM-AS1 | Oxaliplatin | miR-137 |
-YBX1 - Notch1 which induces upregulating MRP-1 and BcL-2 |
Inhibition of cytotoxicity | [25, 128, 203] |
| Lnc34a | 5-FU | miR-34a | Lactate dehydrogenase | Inhibited | [133, 204] |
| ENST00000455974 |
Doxorubicin, 5-FU, Oxaliplatin |
– | JAG2 | Decreased apoptosis | [131, 205] |
| FAM83H‑AS1 | 5-FU | – |
-Notch1 which induces upregulating MRP-1 & BcL-2 -Hes1 which induces upregulating ABCC1, ABCC2, P-gp1 & N-cadherin & suppressing of E-cadherin |
Inhibited | [23, 25, 126] |
| UICLM | 5-FU | – | Notch1 which induces upregulating MRP-1 & BcL-2 | Inhibited | [25, 135] |
| FOXD2-AS1 | 5-FU | – | Hes1 which induces upregulating ABCC1, ABCC2, P-gp1 & N-cadherin & suppressing of E-cadherin | [23, 125] | |
|
GNAS-AS1 RP11-89K10.1 |
5-FU | – | Hes1 which induces upregulating ABCC1, ABCC2, P-gp1 & N-cadherin & suppressing of E-cadherin | [23, 132] | |
| LINC01198 | 5-FU |
-Notch1 which induces upregulating MRP-1 and BcL-2 -Hes1 which induces upregulating ABCC1, ABCC2, P-gp1 & N-cadherin &suppressing of E-cadherin |
Inhibited | [23, 25, 129] | |
| LUNAR1 | 5-FU | IGF-1R | Inhibited | [188, 210] | |